239 related articles for article (PubMed ID: 19672945)
21. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
[TBL] [Abstract][Full Text] [Related]
22. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study.
Li J; Chen P; Dai CH; Li XQ; Bao QL
Geriatr Gerontol Int; 2009 Jun; 9(2):172-82. PubMed ID: 19740361
[TBL] [Abstract][Full Text] [Related]
23. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
[TBL] [Abstract][Full Text] [Related]
24. [Myelotoxicity due to chemotherapy in oncology practice].
Geoffrois L
Rev Prat; 2006 Nov; 56(18):2009-14. PubMed ID: 17274503
[TBL] [Abstract][Full Text] [Related]
25. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
[TBL] [Abstract][Full Text] [Related]
26. Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: a retrospective analysis.
Bae S; Yeung Y; Ng S; Craike M; Livingston PM; Chirgwin J
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e54-62. PubMed ID: 22989364
[TBL] [Abstract][Full Text] [Related]
27. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
28. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.
Schwenkglenks M; Pettengell R; Jackisch C; Paridaens R; Constenla M; Bosly A; Szucs TD; Leonard R
Support Care Cancer; 2011 Apr; 19(4):483-90. PubMed ID: 20306092
[TBL] [Abstract][Full Text] [Related]
30. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
[TBL] [Abstract][Full Text] [Related]
31. Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age.
Peintinger F; Georgoulopoulos A; Ralph G; Piswanger C
J Chemother; 2006 Dec; 18(6):656-61. PubMed ID: 17267346
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
33. Do elderly cancer patients achieve an adequate dose intensity in common clinical practice?
Luciani A; Marussi D; Ascione G; Caldiera S; Ferrari D; Oldani S; Uziel L; Zonato S; Foa P
Oncology; 2006; 71(5-6):382-7. PubMed ID: 17851263
[TBL] [Abstract][Full Text] [Related]
34. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
35. Poor prognosis in elderly patients with cancer: the role of bias and undertreatment.
Dale DC
J Support Oncol; 2003; 1(4 Suppl 2):11-7. PubMed ID: 15346995
[TBL] [Abstract][Full Text] [Related]
36. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
[TBL] [Abstract][Full Text] [Related]
37. Local control, toxicity, and cosmesis in women younger than 50 enrolled onto the American Society of Breast Surgeons MammoSite Radiation Therapy System registry trial.
Khan AJ; Vicini F; Beitsch P; Haffty B; Quiet C; Keleher A; Garcia D; Snider H; Gittleman M; Zannis V; Kuerer H; Whitacre E; Whitworth P; Fine R
Ann Surg Oncol; 2009 Jun; 16(6):1612-8. PubMed ID: 19319606
[TBL] [Abstract][Full Text] [Related]
38. Re: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Russo A; Autelitano M; Bisanti L
J Natl Cancer Inst; 2006 Dec; 98(24):1826-7. PubMed ID: 17179484
[No Abstract] [Full Text] [Related]
39. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.
Castagnola E; Fontana V; Caviglia I; Caruso S; Faraci M; Fioredda F; Garrè ML; Moroni C; Conte M; Losurdo G; Scuderi F; Bandettini R; Tomà P; Viscoli C; Haupt R
Clin Infect Dis; 2007 Nov; 45(10):1296-304. PubMed ID: 17968824
[TBL] [Abstract][Full Text] [Related]
40. Chemotoxicity recurrence in older patients: Risk factors and effectiveness of preventive strategies-a prospective study.
Extermann M; Reich RR; Sehovic M
Cancer; 2015 Sep; 121(17):2984-92. PubMed ID: 26033177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
